FIGURE 2.

SGL5213 improved renal function in an adenine‐induced renal failure model. (a) Plasma glucose, urine glucose, and 1,5‐AG levels in adenine‐induced renal failure model. (b) The plasma BUN, Cr, Urea, allantoin, and cholesterol levels in adenine‐induced renal failure model mice treated with SGL5213 (10 mg/kg/day) for 14 days. Cont: control group (n = 8); RF; renal failure group (n = 6); RF treated with SGL5213 (10 mg/kg/day) group (n = 8–9 each). (c) The plasma TCA component levels. (d) The plasma level of IS, PS, and TMAO in the adenine‐induced renal failure model. Cont; control group (n = 8), RF: renal failure group (n = 6), RF treated with SGL5213 (10 mg/kg/day) group (n = 8–9 each). Data were mean ± SEM. Statistical analysis was performed using a Dunnett's test. *p < 0.05 and ***p < 0.01 were treated as statistically significant